Retrospective study of small pet tumors treated with Artemisia annua and iron

Saeed, Mohamed E.M.; Breuer, Elmar; Hegazy, Mohamed‐Elamir F.

doi:10.3892/ijo.2019.4921

Cited by 11 publications

(9 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an anti-malaria agent, ART induced reactive oxygen species (ROS) due to the high iron content in the Plasmodium parasites, thereby destroying the malaria pathogen [ 17 , 18 ] by ferroptosis, an iron- and ROS-dependent controlled cell death. Tumor cells also contain more iron than normal cells [ 19 , 20 ], most probably due to highly expressed transferrin receptors [ 19 , 20 , 21 , 22 , 23 , 24 ], which might, at least partially, explain why ART specifically affects some tumor cells [ 25 , 26 , 27 , 28 ]. In doxorubicin-resistant T-cell leukemia and cisplatin-resistant neuroblastoma, ART provoked the generation of reactive oxygen species (ROS), contributing to apoptosis induction [ 14 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

Zhao¹,

Vakhrusheva²,

Markowitsch³

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

Cisplatin, which induces DNA damage, is standard chemotherapy for advanced bladder cancer (BCa). However, efficacy is limited due to resistance development. Since artesunate (ART), a derivative of artemisinin originating from Traditional Chinese Medicine, has been shown to exhibit anti-tumor activity, and to inhibit DNA damage repair, the impact of artesunate on cisplatin-resistant BCa was evaluated. Cisplatin-sensitive (parental) and cisplatin-resistant BCa cells, RT4, RT112, T24, and TCCSup, were treated with ART (1–100 µM). Cell growth, proliferation, and cell cycle phases were investigated, as were apoptosis, necrosis, ferroptosis, autophagy, metabolic activity, and protein expression. Exposure to ART induced a time- and dose-dependent significant inhibition of tumor cell growth and proliferation of parental and cisplatin-resistant BCa cells. This inhibition was accompanied by a G0/G1 phase arrest and modulation of cell cycle regulating proteins. ART induced apoptos is by enhancing DNA damage, especially in the resistant cells. ART did not induce ferroptosis, but led to a disturbance of mitochondrial respiration and ATP generation. This impairment correlated with autophagy accompanied by a decrease in LC3B-I and an increase in LC3B-II. Since ART significantly inhibits proliferative and metabolic aspects of cisplatin-sensitive and cisplatin-resistant BCa cells, it may hold potential in treating advanced and therapy-resistant BCa.

show abstract

Section: Introductionmentioning

confidence: 99%

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

Zhao¹,

Vakhrusheva²,

Markowitsch³

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…In closing, we concur with ethical and scientific appeals for a more effective, combinatorial, and comparative oncology, as championed by Thomas Efferth, whose scholarship has done much to reveal the efficacy of Artemisinin's (selective ferroptosis) in combination with chemotherapies for both medical and veterinary oncology [120][121][122], presenting a positive challenge to consider the spontaneous cancers in companion animals as both vital and opportune [123]. It is with confidence in the unity of nature and homeostasis-as reflected in these hard-won molecular, cellular, and genetic understandings that we can expect to learn more about managing cancer metastasis within ourselves, by targeting tumors and managing extended remissions in veterinary medicine.…”

Section: Pathotropic Vector Production: "Points To Consider" For a Comparative Oncologymentioning

confidence: 83%

Lesion-Targeted Anti-Cancer Gene Delivery with Clinical Survival Benefits: A Molecular “Rosetta Stone” for Veterinary Hematology-Oncology and Precision Gene Therapy

Gordon

2021

BJSTR

View full text Add to dashboard Cite

This review represents a series of medical hematology-oncology papers by Gordon, Chawla and Hall, composed with the following intents and purposes: (i) documenting significant milestones in Tumor Targeting and Cancer Gene Therapy for the postmodern biomedical and veterinary research communities, (ii) honoring forthright principles of scientific responsibility, regulatory oversight, and informed consent, which serve to protect both human and companion animal health, and (iii) translating FDA-qualified, updated methods & compositions (CMC and cGMP insights) to veterinary medicine, in light of recent critical analyses, hence gains, in long-term cancer-free survival data achieved in humans. The focus is on tumor-targeted, injectable gene therapy vectors and molecular approaches developed by Gordon and Hall at USC / Children's Hospital Los Angeles-validating "Pathotropic" (disease-seeking) tumor targeting Avant la Lettre. The discussion provides clinical insights into the cellular and molecular mechanisms of both tumor-targeting and tumor-eradication, which led to the formal return of Rexin-G as DeltaRex-G from industrial desuetude to cGMP bioproduction in 2018-2019, with FDA Expanded Access, under a decidedly academic non-profit banner, in accord with historic U.S. "Right-to-Try" legislation. In the spirit of academic fellowship and the interests of a rightfully concerned society, this article provides a molecular (cellular and genetic) "Rosetta Stone" for the responsible translation and biotechnology transfer of these clinically validated U.S. FDA-evolved Pathotropic (i.e., disease-seeking) tumor targeting Methods and Compositions safely to Veterinary Medicine as preclinical safety and efficacy studies in mice, rats, rabbits, minipigs and monkeys were required by the USFDA prior to authorization to use DeltaRex-G in first-in-human clinical trials.

show abstract

“…Finally, in the field of veterinary oncology, artemisinins have shown anticancer activity in preliminary veterinary tumors of dogs and cats 196 . No toxicity and adverse effects were observed in dogs with nonresectable tumors after treatment with artesunate for 7 days and 385 days 197 .…”

Section: Anticancer Action Of Artemisininsmentioning

confidence: 97%

Recent pharmacological advances in the repurposing of artemisinin drugs

Meng

Lyu

Wong

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Artemisinins are a family of sesquiterpene lactones originally derived from the sweet wormwood (Artemisia annua). Beyond their well‐characterized role as frontline antimalarial drugs, artemisinins have also received increased attention for other potential pharmaceutical effects, which include antiviral, antiparsitic, antifungal, anti‐inflammatory, and anticancer activities. With concerted efforts in further preclinical and clinical studies, artemisinin‐based drugs have the potential to be viable treatments for a great variety of human diseases. Here, we provide a comprehensive update on recent reports of pharmacological actions and applications of artemisinins outside of their better‐known antimalarial role and highlight their potential therapeutic viability for various diseases.

show abstract

Retrospective study of small pet tumors treated with Artemisia annua and iron

Cited by 11 publications

References 89 publications

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

Lesion-Targeted Anti-Cancer Gene Delivery with Clinical Survival Benefits: A Molecular “Rosetta Stone” for Veterinary Hematology-Oncology and Precision Gene Therapy

Recent pharmacological advances in the repurposing of artemisinin drugs

Contact Info

Product

Resources

About